**Core Concept**
The clinical presentation of severe headaches, dysphagia, oral lesions, skin thickening, and "stone facies" is highly suggestive of **scleroderma**, a chronic autoimmune disease characterized by excessive collagen deposition and fibrosis. The most specific autoantibody in this condition targets **topoisomerase I**, a nuclear enzyme involved in DNA replication and transcription.

**Why the Correct Answer is Right**
In systemic sclerosis (scleroderma), **anti-topoisomerase I (Scl-70)** autoantibodies are the most specific and common markers. These antibodies are present in approximately 20–30% of patients with limited cutaneous scleroderma and are strongly associated with **diffuse cutaneous scleroderma**, severe skin involvement, and higher risk of pulmonary fibrosis and vascular complications. The presence of Scl-70 is highly predictive of disease severity and long-term outcomes.

**Why Each Wrong Option is Incorrect**
Option A: C-ANCA (anti-proteinase-3) is associated with **granulomatosis with polyangiitis (GPA)**, not scleroderma. It targets neutrophil granule proteins and is linked to vasculitis, not fibrosis or oral lesions.
Option B: Double-stranded DNA antibodies are found in **systemic lupus erythematosus (SLE)**, not scleroderma. SLE presents with photosensitivity, nephritis, and serositis, not stone facies or skin thickening.
Option C: P-ANCA (anti-myeloperoxidase) is linked to **microscopic polyangiitis** and vasculitis, not fibrotic skin disease. It is not specific to scleroderma.

**Clinical Pearl / High-Yield Fact**
Anti-Scl-70 is the most specific autoantibody in scleroderma and is a key diagnostic marker. Patients with this antibody are at higher risk for **interstitial lung disease** and **digital ulcers**—a hallmark of the disease.

✓ Correct Answer: D. Scl-70 (anti-topoisomerase I)